Allergic Rhinitis Rates Forecast to Increase to 1.8bn Individuals in 2011 - Asthma and COPD Figures also on the Rise.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42316) has announced the addition of The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011 to their offering.

The prevalence of asthma in 2005 across the US, Japan, France, Germany, Spain, Italy and the UK was estimated at 53.2m people, corresponding to a prevalence rate of 7.7%. The highest prevalence rate for asthma in any country in 2005 was 12.0% in the UK. It is forecast that by 2011, the total prevalence of asthma across the seven major markets will be 58.8m sufferers or 8.0% of the population. COPD is only significantly prevalent in adults, a contrary situation to that of asthma, in which pediatric patients are estimated to represent some 35% of the total asthmatic patient population across the 7 major markets. 56.4m individuals are estimated to suffer from COPD across the seven major markets, although extremely low rates of diagnosis are thought to have resulted in a treated population of less than 10m individuals.

Increasingly, COPD is becoming a major disease burden across the seven major markets, with a forecast patient population of 60.8m individuals by 2011, indicating high levels of future patient potential. Currently the treatment of asthma/COPD favors the use of beta-2 agonists and inhaled corticosteroids, with leukotriene antagonists and anticholinergics being positioned as additional therapies in either pediatric or last-line patients. With an estimated patient potential of 1.5bn in 2005, allergic rhinitis (AR) is associated with the largest disease burden of any major chronic respiratory disease by virtue of its high prevalence and its impacts on quality of life and productivity. It is believed that AR and asthma frequently co-exist and AR is a significant risk factor for asthma. Across the seven major markets, the prevalence of AR is forecast to increase to 1.8bn individuals in 2011, driven by the effect of raised levels of allergenic exposure, in both indoor and outdoor environments.

Key Questions Answered in this Report:

- What will be the major growth indications in the respiratory area over the period 2005-11?

- How does the performance of major brands in 2004 compare to that in 2005?

- How significant is the threat of generic competition to the overall performance of the asthma, COPD and allergic rhinitis markets?

- Which companies are best positioned to succeed in the global respiratory market over the period 2005-11?

- What are the forecast market size and growth rates over the period 2005-2011 across the major respiratory indications?

- Which R&D compounds are likely to make a major impact on the asthma, COPD and allergic rhinitis markets?

Reasons to Order your Copy:

- Discover which brands have the greatest potential to develop market share and how major players are attempting to exploit these lifecycle management opportunities.

- Compare the franchises of top pharmaceutical marketers across major indications, including GSK, Merck & Co, Boehringer Ingelheim and AstraZeneca and understand their strategy for growth in the respiratory area.

- Use head-to head comparisons of the respiratory pipelines of the 8 leading players to understand which companies are likely to be market leaders in asthma, COPD and allergic rhinitis over the next 5 years.

- Identify the most promising compounds in clinical development and understand how these future product launches will impact the dynamics of the respiratory market

- Drive your company's future growth prospects by examining which of the major respiratory indications are set to increase in prevalence over the next 5 years.

Companies Mentioned:

GlaxoSmithKline
Merck & Co
Boehringer Ingelheim
AstraZeneca
Schering-Plough
Sanofi-Aventis
Pfizer
Pfizer
Novartis

For more information visit http://www.researchandmarkets.com/reports/c42316